Putnam BioRevolution ETF
Data updated: 2025-12-29
C000237308 — Putnam BioRevolution ETF. United States Large Cap Growth Equity · $4.66M AUM · 0.70% expense ratio. Holdings, fees, performance and SEC filings.
C000237308 Fund Overview
Putnam BioRevolution ETF is a US ETF managed by Putnam ETF Trust, categorised as United States Large Cap Growth Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Putnam ETF Trust
- Category: United States Large Cap Growth Equity
- Assets under management: $4.66M
- 1-year return: -0.6%
- SEC CIK: 0001845809
- SEC series ID: S000077138
- Share class ID: C000237308
C000237308 Investment Objective and Strategy
Putnam BioRevolution ETF describes its objective and strategy as follows, from its latest prospectus filed with the SEC by Putnam ETF Trust.
Investment objective
The fund seeks long-term capital appreciation.
Principal investment strategy
The fund invests mainly in common stocks (growth or value stocks or both) of companies worldwide of any size with a focus on biology revolution companies. Biology revolution companies are companies that the Investment Manager, as defined below, believes offer the opportunity to capitalize on a convergence of technological developments in the life sciences sector that change the ability to understand and design biology to scale and include technology-enabling companies, biotechnology or synthetic biology companies, and existing companies that may benefit from the biology revolution in certain cases by reducing operational risks (i.e., providing supply chain redundancy or sourcing of new or rare materials), mitigating environmental risks (i.e., reducing greenhouse gas emissions), and/or fostering consumer demand for the companys products.
Technology-enabling companies have products that contribute to the research, development, production, diagnosis, and treatment of biology. Examples of these products include instruments like DNA sequencers, mass spectrometers, electron microscopes and PCR technology that have helped enable advances in the fields of genomics, proteomic, and cell research. The Investment Manager believes that technology-enabling companies have the potential for increased demand for their products from companies engaged in biological research or development of biological products. Synthetic biology companies are companies that manufacture products made from biological materials, including companies that are engaged in redesigning organisms for useful purposes by engineering them to have new abilities to solve problems in medicine, manufacturing, and agriculture.
Examples would include companies in the plant-based or alternative meat industries. Stocks of biology revolution companies are typically, but not always, considered to be growth stocks. Growth stocks are stocks of companies whose revenues, earnings, or cash flows are expected to grow faster than those of similar firms, and whose business growth and other characteristics may lead to an increase in stock price. Under normal circumstances, the fund invests at least 80% of the funds net assets in equity securities of biology revolution companies. This policy is non-fundamental and may be changed only after 60 days notice to shareholders. From time to time, the fund may invest a significant portion of its assets in companies in one or more related industries or sectors, including the health care, consumer discretionary, consumer staples, biotechnology and materials sectors.
The Investment Manager may consider, among other factors, a companys valuation, financial strength, growth potential, competitive position in its industry, projected future earnings, cash flows and dividends when deciding whether to buy or sell investments. The Investment Manager may also consider other factors that it believes will cause the stock price to rise. The fund is non-diversified, which means it may invest a greater percentage of its assets in fewer issuers than a diversified fund. The fund expects to invest in a limited number of issuers.
C000237308 Holdings
Top 10 holdings of Putnam BioRevolution ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Thermo Fisher Scientific Inc | 9.18% |
| AbbVie Inc | 5.37% |
| NVIDIA Corp | 5.14% |
| Corteva Inc | 4.89% |
| Bio-Rad Laboratories Inc | 4.77% |
| Putnam Government Money Market Fund | 4.76% |
| Ascendis Pharma A/S | 4.69% |
| Novonesis Novozymes B | 4.54% |
| AstraZeneca PLC | 4.46% |
| Eli Lilly & Co | 3.94% |
C000237308 Portfolio Allocation
Asset-class allocation of Putnam BioRevolution ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 95.2% |
| Cash & Equivalents | 4.8% |
C000237308 Performance
Total returns for C000237308 (as of 2026-10-01), from SEC filings.
| Period | Total return |
|---|---|
| 1 year | -0.6% |
| 3 years (annualised) | 7.0% |
C000237308 Risk Information
Risk metrics for C000237308, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 12.2%
C000237308 Costs and Fees
C000237308 costs about $70 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.70%
- Gross expense ratio: 0.70%
- Portfolio turnover: 32%
- Brokerage commissions: 1.07 bps of average net assets (SEC N-CEN)
C000237308 Cashflows
Over the 12 months to 2025-10, Putnam BioRevolution ETF had net outflows of $791.88K, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2025-10 | −$791.88K |
| 2025-09 | $0 |
| 2025-08 | $0 |
| 2025-07 | $0 |
| 2025-06 | $0 |
| 2025-05 | $0 |
C000237308 Debt Constituents
No individual debt constituents are reported in Putnam BioRevolution ETF's latest SEC N-PORT filing.
C000237308 Prospectus and SEC Filings
Official Putnam BioRevolution ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2025-08-25
- Prospectus (485BPOS) — filed 2024-08-27
- Prospectus (485BPOS) — filed 2023-08-24
- Portfolio holdings (N-PORT) — filed 2025-12-29
- Portfolio holdings (N-PORT) — filed 2025-09-10
- Portfolio holdings (N-PORT) — filed 2025-06-18
- Annual census (N-CEN) — filed 2025-07-14
- Annual census (N-CEN) — filed 2024-07-12
Related Funds
Other United States Large Cap Growth Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.